Lenovo Delivers Robust Revenue and All-Time Record Pre-Tax Income for FY19/20, Weathering Global Economic Challenges to Emerge in Position of Strength
Lenovo Group (HKSE: 992) (OTC Pink: LNVGY) today announced robust results for its full fiscal year and Q4, demonstrating the company’s position of strength amid unprecedented global transformation. Despite a fiscal year full of macro-economic and industry challenges, the company delivered full-year revenue exceeding US$50 billion (US$50.7 billion) for the second consecutive year. Profitability remained a strength, with historical high pre-tax income of US$1.02 billion, up almost 19% year-on-year. Full-year Net Income was US$665 million, up 12% year-on-year.
Basic earnings per share for the full year were 5.58 US cents or 43.61 HK cents, and for the fourth quarter the figure was 0.36 US cents or 2.80 HK cents. Lenovo’s Board of Directors declared a final dividend of 2.77 US cents or 21.50 HK cents per share for the fiscal year ended March 31, 2020.
“Amid one of the most significant periods of global change and transformation we have ever seen, Lenovo significantly transformed its business over the past year. From achieving record PTI of US$1.02 billion to reaching near record revenue of US$50.7 billion, I could not be prouder of our strong performance,” said Yang Yuanqing, Lenovo Chairman and CEO. “I am also unbelievably proud of how we continue to respond to the global pandemic, as both a business and a corporate citizen. While the world continues to face uncertain times, I’m confident Lenovo will leverage its operational excellence and global footprint to continue implementing our intelligent transformation strategy and fully grasp the opportunities our ‘new norm’ provides us.”
Global Economic Factors and Outlook
The last 12 months presented several industry-wide challenges, including geo-political uncertainties, component supply shortages, currency exchange impact, and in the fourth quarter the global COVID-19 pandemic. As relates to coronavirus, the business leveraged the power of 30+ inhouse and third-party manufacturing sites around the world to adjust capacity and rebalance production. This geographical balance and innate flexibility and resilience was at the core of the operational excellence shown throughout the year, ensuring the company continued to manufacture products and deliver orders to customers throughout Q4. Looking ahead, this foundational capability, together with ongoing innovation, will continue to drive business as the company seizes the long-term growth opportunities that the ‘new normal’ of working and studying from home is creating. This trend is not only leading to a growth in PC and smart devices, but also in the supporting data centers and infrastructure to power faster networks and digital consumption.
Fiscal Year Business Group Overview
Lenovo’s Intelligent Devices Group (IDG) continues to lead the company’s strong performance. The PC and Smart Devices group (PCSD), one of the two IDG business units, led the way with revenue for the year of almost US$40 billion, up 3.6% year-on-year. Profitability improved, with pre-tax income a record high of US$2.3 billion (more than 18% year-on-year) and an industry leading and record high PTI margin of 5.9%, up 0.7 points year-on-year. Leadership of the overall global PC market was extended, with share up more than 1 percentage point at 24.5% for the full year. This strong sustainable growth is driven by a consistent strategy to focus on and invest in high-growth segments, with Gaming, Workstations, Visuals, Thin and Light and Chromebooks each outgrowing the market by double-digits in volume.
IDG’s second business group, the Mobile Business Group (MBG), was on target for a breakthrough year until the fourth quarter impact of the required closure of the company’s primary smartphone factory in Wuhan due to COVID-19. Overall MBG revenue declined and pre-tax loss was US$43 million, greatly narrowed by US$96 million year-on-year. The business continued its focus on innovation, reentering the premium segment with the iconic foldable Motorola razr smartphone.
The Data Center Group (DCG) saw overall revenue decline 8.7% year-on-year due to softer Hyperscale demand and significant commodity price declines, but non-hyperscale revenue grew 5.3% year-on-year. This was driven by double-digit revenue growth in Software Defined Infrastructure (SDI), Storage, Software and Services. In particular storage revenue grew more than 50% year-on-year. In addition, non-hyperscale server volume grew by 14% and China revenue by 23% year-on-year. The company also extended its #1 leadership in High Performance Computing with 173 of the top 500 systems worldwide now running on Lenovo.
Transformation businesses demonstrated solid progress. Smart IoT revenue almost quadrupled (+296%) year-on-year driven by augmented and virtual reality, Smart Office and Internet of Things. Smart Infrastructure grew 37% year-on-year as Network Function Virtualization started to generate revenue. And Smart Vertical revenue more than doubled (+133%) thanks to strong growth in Data Intelligence Business Group, smart healthcare and smart education solutions. Software and Services had a breakthrough year with record revenue* of US$3.5 billion, up 43.2% year-on-year and becoming the catalyst for the Group’s overall transformation.
- Group revenue for the quarter was US$10.6 billion, down 9.7% year-on-year. Pre-tax income was US$77 million and Net income US$43 million.
- PC and Smart Devices delivered a strong quarter. Revenue was down 4.4% year-on-year, but pre-tax Income improved by 15% (US$525 million v US$458 million) year-on-year, extending the company’s industry leading profitability by 1 whole point to a record high of 6.2%.
- PC volume outgrew the market by four points, extending the company’s leadership and #1 global market position. PC revenue outgrew the market in all geographies around the world.
- The Mobile Business Group was impacted by COVID-19 with the company’s primary global smartphone factory in Wuhan shut for much of the quarter. Despite this the business leveraged its global manufacturing footprint and produced 6 million phones during the quarter.
- In Data Center, server volume continued double-digit growth (14%) year-on year. Hyperscale revenue remained a challenge due to a significant commodity price drop, but non-hyperscale business grew revenue almost 4% year-on-year, driven by the key growth and profit driver segments of Software Defined Infrastructure, Storage, Software and Services.
* Invoiced revenue
Lenovo (HKSE: 992) (OTC Pink: LNVGY) is a US$50 billion Fortune Global 500 company, with 63,000 employees and operating in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that create a more inclusive, trustworthy and sustainable digital society. By designing, engineering and building the world’s most complete portfolio of smart devices and infrastructure, we are also leading an Intelligent Transformation – to create better experiences and opportunities for millions of customers around the world. To find out more, visit https://www.lenovo.com, follow us on LinkedIn, Facebook, Twitter, YouTube, Instagram, Weibo and read about the latest news via our StoryHub.
For the fiscal quarter and full year ended March 31, 2020
(in US$ millions, except per share data)
Gross profit margin
Other non-operating expenses - net
Profit for the period/year
Profit attributable to equity holders
Earnings per share (US cents)
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 20:31:00 CEST | Press release
Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu
Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r
Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 14:00:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo
Takeda to Present Data from the ICLUSIG ® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 14:00:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the 25thEuropean Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR-A
Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 14:00:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25thEuropean Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leukemi
LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 13:57:00 CEST | Press release
LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom